Login to Your Account

Financings Roundup

Still Seeking Partner, Anadys Adds $25M for HCV Drug Trial

By Jennifer Boggs

Monday, October 18, 2010
Having yet to sign a partnership for hepatitis C drug ANA598, Anadys Pharmaceuticals Inc. is pulling in $25 million in a public offering to support an upcoming Phase IIb study of the non-nucleoside polymerase inhibitor. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription